Morgan Stanley said it was overweight on the stock and there was 22% upside in the counter in the next 12 months. The brokerage house has set a price target of Rs 981. | Subscribe To Our Free Newsletter |
Brokers turn bullish on Sun Pharma
Morgan Stanley said it was overweight on the stock and there was 22% upside in the counter in the next 12 months. The brokerage house has set a price target of Rs 981. 